MarketCap
Verrica Pharmaceuticals VRCA
$ 3.4
-14.14%
Facebook
X
Telegram
Verrica Pharmaceuticals Cost of Revenue | VRCA
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Verrica Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 2.6 M | 500 K | - | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.6 M | 500 K | 1.55 M |
Quarterly Cost of Revenue Verrica Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 700 K | - | - | 700 K | 700 K | - | 300 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 700 K | 300 K | 600 K |
Cost of Revenue of other stocks in the Biotechnology industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Guardion Health Sciences
GHSI
|
6.85 M | - | -0.31 % | $ 3.64 M |  USA |
 |
Opiant Pharmaceuticals
OPNT
|
13.7 M | - | - | $ 109 M | USA |
 |
Otonomy
OTIC
|
370 K | - | -1.96 % | $ 4.68 M | USA |
 |
Seagen
SGEN
|
410 M | - | - | $ 42.2 B | USA |
 |
Baudax Bio
BXRX
|
7.01 M | - | 0.59 % | $ 63 K | USA |
 |
Avid Bioservices
CDMO
|
133 M | - | - | $ 789 M | USA |
 |
Zosano Pharma Corporation
ZSAN
|
796 K | - | 7.23 % | $ 2.72 M | USA |
 |
Spectrum Pharmaceuticals
SPPI
|
1.79 M | - | - | $ 189 M | USA |
 |
Vascular Biogenics Ltd.
VBLT
|
197 K | - | -8.77 % | $ 12.4 M |  Israel |
 |
Berkeley Lights
BLI
|
24.8 M | - | -7.31 % | $ 87 M | USA |
 |
VBI Vaccines
VBIV
|
9.17 M | - | -50.87 % | $ 1.09 M | USA |
 |
Certara
CERT
|
161 M | $ 10.61 | 2.66 % | $ 1.7 B | USA |
 |
CTI BioPharma Corp.
CTIC
|
3.51 M | - | - | $ 1.2 B | USA |
 |
PolarityTE
PTE
|
616 K | - | -0.82 % | $ 1.78 M | USA |
 |
Trevena
TRVN
|
1.67 M | - | -46.58 % | $ 31.8 M | USA |
 |
Y-mAbs Therapeutics
YMAB
|
15 M | - | - | $ 382 M | USA |
 |
Navidea Biopharmaceuticals
NAVB
|
1.94 K | - | -2.99 % | $ 2.47 M | USA |